Publication of the 2019 Half-Yearly Financial Report
Paris (France), July 31, 2019 – 7.00 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” […]
Onxeo Announces its Financial Agenda for 2020
Paris (France), December 9, 2019 – 05:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or […]
Onxeo Announces Publication of Preclinical Study Results Comparing Efficacy and Toxicity of olaparib and AsiDNA™ in Frontiers in Oncology
In-vivo Models Showed that Only AsiDNA™ Could Delay Resistance to Carboplatin without Increasing its Toxicity Paris (France), November 13, 2019 […]
Direct Dirigeants
DIRECT DIRIGEANTS A debate during which Onxeo’s executives present the company’s development strategy, activities, results and prospects. Organized by les […]
Tides Europe 2019 – Oligonucleotide & Peptide Therapeutics
Tides Europe 2019 Learn more …. Download management presentation Download poster
Bryan, Garnier & Co European Healthcare Conference
Bryan, Garnier & Co European Healthcare Conference Download management presentation
Onxeo to attend the European Healthcare Conference organized by Bryan, Garnier & Co.
Paris (France), November 5, 2019 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Onxeo Receives U.S. Patent and Trademark Office Notice of Allowance for New Patent Protecting Combination of AsiDNA™ with Any PARP Inhibitor for Cancer Treatment
Combination patent to be granted in the U.S. until 2036 Paris (France), November 4, 2019 – 5:45 pm CEST – […]
Onxeo, Winner of the Innov’up Leader PIA Call for Projects, Receives Funding of €495,000
The winning project aims to develop a drug candidate in immuno-oncology from the platON™ platform Funding from the French State […]
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics The premier international meeting featuring novel cancer therapeutics. Read more […]
Onxeo to Present Final Results of DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Positive Safety and Activity Results from DRIIV-1 Led to Initiation of Ongoing DRIIV-1b Phase 1b Study of AsiDNA™ in Combination […]
Onxeo receives EPO Intent-to-Grant Notice for New Patent strengthening European Protection of Compounds sourced from its platON™ Platform
This new patent protects in particular AsiDNA™ and its related compounds for their use in the treatment of cancer, alone […]
Onxeo announces positive intermediate results from the first part of the DRIIV-1b study evaluating AsiDNA™ in combination with chemotherapy
Stabilized disease without tumor progression for two of the three treated patients who are still receiving treatment with AsiDNA™ […]
Investir Day
Investir Day For more information : www.investirday.fr (French only) Download the management presentation (in French)
DNA Damage Response Therapeutics Summit 2019
DNA Damage Response Therapeutics Summit 2019 Access Management Presentation
Portzamparc MidCap 2019
Portzamparc MidCap 2019 Access Management Presentation
2019 BIO International Convention
2019 BIO International Convention Access Management Presentation
CM-CIC Market Solutions Forum
CM-CIC Market Solutions Forum Access Management Presentation
Meetings during JP Morgan Conference
Meetings during JP Morgan Conference Access Management Presentation
Biomed Event 2019
Biomed Event 2019 Access Management Presentation
Onxeo to Attend Key Investor and Scientific Conferences
Paris (France), September 11, 2019 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO – FR0010095596), (“Onxeo” or “the Company”), […]
Galien Medstartup 2019
GALIEN MEDSTARTUP 2019 For more information : medstartup.galienfoundation.org
Ordinary General Meeting on April 26, 2019
Paris (France), April 5, 2019 – 10 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company […]
Ordinary General Meeting of May 22, 2019
Renewal of the terms of office of Danièle Guyot-Caparros, Jean-Pierre Bizzari and Jean-Pierre Kinet Appointment of Danièle Guyot-Caparros as Chairman […]
Onxeo announces final positive data from DRIIV-1 Phase 1 Study of AsiDNA™ in Advanced Solid Tumors
Primary safety and activity endpoints met Favorable safety profile, maximum tolerated dose not reached, optimal active dose determined AsiDNA™ induced […]
Onxeo renews its equity financing line with Nice & Green as part of the financing of its business and strategic activities
The new financing line could represent a total of approximately €9 million over the upcoming 12 months, based on current […]
Onxeo Expands its Pipeline with New Optimized Lead OX401 Entering Proof-of-Concept Preclinical Phase
OX401 is the second candidate utilizing Onxeo’s proprietary platform of decoy agonists, platON™ OX401 is optimized to be a next-generation […]
The equity research company KEPLER CHEUVREUX initiates the coverage of ONXEO with a “Buy” recommendation
Paris (France), July 1st, 2019 – 7:00 a.m. CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (hereinafter “Onxeo” or […]
Onxeo Reports Half-Year 2019 Financial Results and Provides Business Update
Finalization of DRIIV-1 Phase 1 study confirming AsiDNA™ activity and safety profile Initiation of DRIIV-1b study of AsiDNA™ with chemotherapy, […]
Onxeo Announces Identification of Predictive Biomarkers for AsiDNA™, its First-in-Class DNA Damage Response Inhibitor
Biomarkers correlated to tumoral sensitivity to AsiDNA™, supporting personalized medicine approaches A selection tool to screen patients in future clinical […]
Onxeo to Present Five Preclinical Studies Highlighting AsiDNA™ Unique Profile and its clinical potential in Oncology at 2019 American Association for Cancer Research Annual Meeting
Paris (France), February 13, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Onxeo Reports Full-Year 2018 Financial Results and Provides Business Update
Clinical development of AsiDNA™ continues in phase 1 study DRIIV-1 Activity of AsiDNA™ demonstrated through the marked activation of its […]
Onxeo to Present Data supporting Lead Asset AsiDNA™ in 5 Poster Presentations at 2019 American Association for Cancer Research Annual Meeting
Paris (France), March 25, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]
Publication of the 2018 Registration Document
Paris (France), April 8, 2019 – 5:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company […]
Onxeo Announces Treatment of First Patient in DRIIV-1b, a Phase 1b Clinical Trial of AsiDNA™ in Combination with Chemotherapy
DRIIV-1b is designed to assess the clinical potential of AsiDNA™ in combination with carboplatin and with carboplatin plus paclitaxel in […]